BiVictriX Therapeutics secures Innovate UK grant to advance ovarian cancer treatment
BiVictriX Therapeutics plc (AIM: BVX), a pioneering drug discovery and development company, has announced receiving a substantial grant of £0.37 million from Innovate UK. This grant is earmarked for accelerating the preclinical development of BiVictriX’s promising new drug, BVX002, which is designed to target ovarian cancer treatment through a novel approach using bispecific antibody drug […]